In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers-Reference-Cited by-同舟云学术

In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Published:2018-02-13 Issue:5 Volume:17 Page:1003-1011
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Altwerger Gary,Bonazzoli Elena,Bellone Stefania,Egawa-Takata Tomomi,Menderes Gulden,Pettinella Francesca,Bianchi Anna,Riccio Francesco,Feinberg Jacqueline,Zammataro Luca,Han Chanhee,Yadav Ghanshyam,Dugan Katherine,Morneault Ashley,Ponte Jose F.,Buza Natalia,Hui Pei,Wong Serena,Litkouhi Babak,Ratner Elena,Silasi Dan-Arin,Huang Gloria S.,Azodi Masoud,Schwartz Peter E.,Santin Alessandro D.

Funder

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

2. The clinical landscape of antibody-drug conjugates in endometrial cancer;International Journal of Gynecologic Cancer;2024-07-29

3. Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications;Cancers;2024-07-04

4. High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options;Reproductive Sciences;2024-04-24

5. An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma;Scientific Reports;2024-03-11